Orphan Drugs, Specialty Therapeutics, Access-Program Architecture & Innovator Commercialisation
Specialty & Rare Disease
Executive Search
50+ Specialty & Rare Disease Placements — with an average 105 Days time-to-placement and a 12-month candidate guarantee.
50+
Specialty & Rare Disease Placements
105 Days
Avg. Time-to-Placement
87%
Offer Acceptance Rate
12 Months
Candidate Guarantee
Specialisation withinPharmaceuticals & Biotechnology·Innovating for Better Health
Specialty and Rare Disease is the innovator-and-orphan-drug tranche of pharma where complex-therapeutic-area commercialisation intersects with patient-access-programme architecture and specialty-distribution rigour. The ecosystem spans MNC innovator India subsidiaries commercialising specialty-and-rare-disease portfolios (leading global pharma innovator India units across oncology, haematology, immunology, and rare disease; global rare-disease and orphan-drug MNC India units; and global biologics-and-specialty MNC India units), listed Indian innovator-and-specialty operators (the specialty-and-proprietary-products arms of the large-cap listed Indian pharma majors, listed Indian innovator R&D operators, and listed Indian specialty-formulations operators), emerging biotech innovators (listed biosimilars-and-novel-biologics operators, specialty arms of listed generics-and-API majors, listed biopharma-and-complex-generics operators, India-headquartered mRNA-platform operators, India-headquartered oncology-and-discovery biotech operators, and cell-and-gene-therapy ventures), and rare-disease patient-advocacy-aligned operators. Leadership here requires fluency in specialty-therapeutic-area (oncology, haematology, rare disease, ophthalmology, nephrology, immunology, neurology, endocrinology, pulmonology) commercialisation, patient-access-programme (PAP) and named-patient-programme architecture, specialty-pharmacy-and-specialty-distribution stewardship, orphan-drug regulatory-and-pricing architecture, and the specific high-touch KOL-and-patient-support operating rhythm.
Is This Your Situation?
If any of these sound familiar, you're speaking to the right practice.
→MNC innovator India subsidiary running MD succession — global-principal-aligned confidential search across specialty-therapeutic-area operating credibility, multi-stakeholder (India-regulator, KOL, patient-advocacy, global-principal) governance, and patient-access-programme architecture stewardship.
→Listed Indian pharma major scaling its specialty-and-innovator book hiring a Head of Specialty with therapy-area-specific commercialisation credibility and KOL-and-medical-affairs-engagement discipline.
→Emerging biotech operator closing a Series B / C round hiring a Head of R&D with discovery-to-clinical translational credibility and the specific biotech-financing-and-milestone-architecture fluency.
→Rare-disease-focused operator scaling its named-patient-programme hiring a Head of Rare Disease with NPRD-and-Centre-of-Excellence-hospital engagement credibility and patient-advocacy-and-diagnosis-pathway architecture.
Our Specialty & Rare Disease Track Record
Situation:
An MNC innovator India subsidiary with a concentrated specialty portfolio across oncology, haematology, and rare disease needed MD succession. The brief required specialty-therapeutic-area operating credibility, global-principal-and-India-regulator stewardship, patient-access-programme architecture fluency, and the multi-stakeholder governance rhythm of an MNC India unit.
Outcome:
Placed an MD with prior country-head tenure at a peer MNC innovator operator and subsequent regional-VP tenure at a global specialty major. Search ran 172 days across a global talent architecture. The India subsidiary's specialty-launch cadence and patient-access-programme expansion compounded materially within 18 months of the MD's joining.
Situation:
A listed Indian pharma major scaling its specialty-and-innovator oncology book needed a Head of Oncology with biomarker-and-targeted-therapy launch credibility and KOL-and-tumour-board-engagement discipline. The brief required specialty-distribution stewardship, medical-affairs-led-commercialisation fluency, and real-world-evidence-generation architecture.
Outcome:
Placed a Head of Oncology with prior head-of-oncology tenure at an MNC innovator operator and subsequent oncology-business-head tenure at a peer listed specialty operator. The operator's oncology book grew materially with multiple biomarker-targeted launches and expanded KOL-engagement-and-tumour-board presence within 18 months of the Head's joining.
Situation:
An emerging India-based oncology biotech closing a cross-border Series C round needed Head of R&D succession. The brief required discovery-to-clinical translational credibility across small-molecule and peptide oncology, IND-enabling and Phase 1-2 clinical-trial stewardship, and the specific biotech-financing-and-milestone architecture fluency.
Outcome:
Placed a Head of R&D with prior head-of-discovery-oncology tenure at a global pharma major and subsequent CSO tenure at a peer India-based oncology biotech. The biotech advanced multiple molecules into IND-enabling and Phase 1 across the subsequent 18 months with materially improved investor confidence and a closed Series C round.
All client details anonymised. Specific mandates available for reference under NDA upon request.
Our Specialty & Rare Disease Practice
Specialty and Rare Disease is the innovator-and-orphan-drug tranche of pharma where complex-therapeutic-area commercialisation intersects with patient-access-programme architecture and specialty-distribution rigour. The ecosystem spans MNC innovator India subsidiaries commercialising specialty-and-rare-disease portfolios (leading global pharma innovator India units across oncology, haematology, immunology, and rare disease; global rare-disease and orphan-drug MNC India units; and global biologics-and-specialty MNC India units), listed Indian innovator-and-specialty operators (the specialty-and-proprietary-products arms of the large-cap listed Indian pharma majors, listed Indian innovator R&D operators, and listed Indian specialty-formulations operators), emerging biotech innovators (listed biosimilars-and-novel-biologics operators, specialty arms of listed generics-and-API majors, listed biopharma-and-complex-generics operators, India-headquartered mRNA-platform operators, India-headquartered oncology-and-discovery biotech operators, and cell-and-gene-therapy ventures), and rare-disease patient-advocacy-aligned operators. Leadership here requires fluency in specialty-therapeutic-area (oncology, haematology, rare disease, ophthalmology, nephrology, immunology, neurology, endocrinology, pulmonology) commercialisation, patient-access-programme (PAP) and named-patient-programme architecture, specialty-pharmacy-and-specialty-distribution stewardship, orphan-drug regulatory-and-pricing architecture, and the specific high-touch KOL-and-patient-support operating rhythm.
We place leaders across MNC innovator India subsidiaries, listed Indian innovator-and-specialty operators, emerging biotech innovators, and rare-disease-focused operators. Engagements include MD / Country Head searches for MNC innovator India subsidiaries, Head of Specialty / Head of Rare Disease searches, Head of Oncology / Head of Haematology / Therapy-Area Head placements, Head of Medical Affairs and Head of Access placements, Head of Innovation / Head of R&D placements for emerging biotech operators, and CFO placements with innovator-and-specialty-accounting credibility. Every mandate is retained and closed-network.
As a specialist MD and Country Head mandates, our practice also covers CMO and specialty commercial leadership, our practice also covers Pharmaceuticals & Biotech practice overview, and as a source for Pharmaceuticals — biosimilars & biologics.
The Specialty & Rare Disease Landscape Today
India's specialty-and-rare-disease tranche is one of the fastest-growing specialty-pharma sub-segments — the Indian specialty-pharma market is estimated at ₹25,000-30,000 crore growing at 13-16% annually, with rare-disease (orphan-drug) estimated at ₹1,500-2,000 crore growing faster still. MNC innovator India subsidiaries — leading global pharma innovator India units across oncology, haematology, immunology, and rare disease (with portfolios spanning targeted oncology biologics, kinase inhibitors, checkpoint inhibitors, biologic disease-modifying agents, complement inhibitors, enzyme-replacement therapies, anti-amyloid therapies, and CFTR-modulator therapies) — commercialise the majority of India's innovator specialty portfolios. Listed Indian operators have built material specialty books — illustrative positions include novel-biologic psoriasis molecules, ophthalmic specialty molecules, listed Indian pharma majors' proprietary-products portfolios, listed biosimilars operators' insulins-and-biosimilars, and novel fixed-dose-combination molecules developed by listed Indian innovator-R&D operators. Emerging biotech operators — India-headquartered oncology-and-discovery biotech operators (small-molecule and peptide oncology), cell-and-gene-therapy ventures (CAR-T), India-headquartered mRNA-platform operators, antibiotics-and-anti-infective discovery specialists, computational-biology specialists, and similar — represent the next-generation tranche. The National Policy for Rare Diseases 2021 (NPRD 2021) provides a one-time treatment-cost support of up to ₹50 lakh per patient for Group 3 rare diseases, funded through Centre-of-Excellence hospitals. Patient-access-programme (PAP), named-patient-programme, compassionate-use, and orphan-drug importation architecture are operating essentials. Specialty-pharmacy-and-specialty-distribution (unlike retail-chemist distribution) is how most specialty products reach patients. KOL-and-patient-advocacy engagement, medical-affairs-led commercialisation, and real-world-evidence-generation discipline define the operating rhythm. Compensation is at the top of Indian pharma bands with material global-principal-aligned LTI architecture.
Key Leadership Challenges in Specialty & Rare Disease
MD / Country Head succession for MNC innovator India subsidiaries commercialising specialty portfolios — leaders with specialty-therapeutic-area operating credibility, global-principal-and-India-regulator stewardship, patient-access-programme architecture fluency, and the governance rhythm of MNC India units.
Head of Specialty / Head of Rare Disease placements — multi-division MNC subsidiaries and listed Indian operators need Division Heads with specialty-therapeutic-area-and-KOL-engagement credibility and PAP-and-access-programme architecture discipline.
Head of Oncology / Head of Haematology / Therapy-Area Head placements — oncology is the single largest specialty tranche; therapy-area leaders need biomarker-and-targeted-therapy launch credibility, KOL-and-tumour-board engagement discipline, and specialty-distribution-and-specialty-pharmacy stewardship.
Head of Medical Affairs / Head of Access placements — specialty operators need Medical Affairs and Access Heads with KOL-engagement credibility, real-world-evidence-generation discipline, NPRD-and-PM-JAY engagement stewardship, and the specific specialty-medical-affairs architecture.
Head of Innovation / Head of R&D placements for emerging biotech operators — novel-molecule-and-novel-platform operators need R&D Heads with discovery-to-clinical translational credibility and the specific biotech-R&D-financing-and-milestone architecture.
Head of Rare Disease / Head of Orphan Drugs placements — rare-disease-focused operators need leaders with named-patient-programme and import-licence architecture, patient-advocacy-and-diagnosis-pathway stewardship, and ultra-rare-disease economics fluency.
What We Look For in Specialty & Rare Disease Leaders
Across mandates, specialty & rare disease leadership tends to cluster into a small set of archetypes. We calibrate each search against the profile your board actually needs — not the one most commonly available.
The MNC Specialty MD / Country Head
Executive who has run an MNC innovator India subsidiary or multi-country MNC specialty P&L — fluent in specialty-therapeutic-area operating credibility, global-principal-and-India-regulator stewardship, patient-access-programme architecture, and the governance rhythm of MNC India units. Often a career MNC-pharma operator with subsequent Country Head or Regional VP leadership.
The Head of Specialty / Rare Disease
Division leader with specialty-therapeutic-area-and-KOL-engagement credibility, PAP-and-access-programme architecture discipline, specialty-pharmacy-and-specialty-distribution stewardship, and the specific innovator-commercialisation rhythm. Often a medical or pharma graduate with subsequent Head of Specialty or Head of Rare Disease leadership.
The Therapy-Area Head (Oncology / Haematology / Immunology)
Segment-specialist commercial leader with biomarker-and-targeted-therapy launch credibility, KOL-and-tumour-board-engagement discipline, specialty-distribution stewardship, and the specific therapy-area commercial rhythm. Often a career oncology-or-specialty commercial operator with subsequent Therapy-Area Head leadership.
The Medical Affairs / Access Head
Leader with KOL-engagement credibility, real-world-evidence-generation discipline, NPRD-and-PM-JAY-engagement stewardship, specialty-medical-affairs architecture fluency, and the specific patient-programmes-and-compassionate-use operating rhythm. Usually a medical graduate (MD / DM) with subsequent industry Medical Affairs leadership.
The Biotech R&D / Innovation Head
R&D leader with discovery-to-clinical translational credibility, multi-platform (small-molecule, biologic, cell-and-gene-therapy, mRNA) discovery stewardship, biotech-financing-and-milestone architecture fluency, and the specific emerging-biotech R&D rhythm. Often a PhD or MD / PhD with industry or academic-founder R&D leadership.
The Rare Disease / Orphan Drugs Head
Division leader with named-patient-programme and import-licence architecture credibility, patient-advocacy-and-diagnosis-pathway stewardship, Centre-of-Excellence hospital engagement fluency, and the specific ultra-rare-disease economics-and-access rhythm. Rare talent profile — often MNC-rare-disease-subsidiary-trained.
Regulatory & Compensation Context
Regulatory Backdrop
Specialty-and-rare-disease operations sit at the intersection of CDSCO (New Drugs and Clinical Trials Rules 2019), the National Policy for Rare Diseases 2021 (NPRD 2021), the Drug Price Control Order (DPCO) / National Pharmaceutical Pricing Authority (NPPA) architecture for innovator pricing, and global regulatory frameworks (USFDA, EMA, PMDA). CDSCO's Subject Expert Committee (SEC) and New Drug Advisory Committee (NDAC) oversee innovator approvals; the accelerated-approval and conditional-approval pathways apply to specific oncology-and-rare-disease indications. NPRD 2021 classifies rare diseases into Group 1 (curable with one-time treatment), Group 2 (long-term / lifelong treatment with relatively lower cost), and Group 3 (definitive treatments available but with high cost / requiring lifelong therapy) — Group 3 patients are eligible for one-time support up to ₹50 lakh through 12 designated Centre-of-Excellence hospitals (leading central government AIIMS, premier medical colleges, and state-level postgraduate medical institutes). Named-patient-programme and compassionate-use import architecture (under CDSCO) governs orphan-drug access for non-approved molecules. NPPA's monitoring and price-fixation authority extends to innovator drugs under specific triggers; recent NPPA orders on innovator oncology molecules illustrate the evolving pricing-control landscape. The Patents Act 1970 (including Section 3(d) and the compulsory-licensing architecture under Section 84) governs innovator-patent-and-generic-challenge architecture. UCPMP 2024 (Uniform Code for Pharmaceutical Marketing Practices, revised 2024) governs KOL-engagement and promotional-spend discipline. DPDP Act 2023 governs patient-programme data handling.
Compensation Architecture
Specialty-and-rare-disease leadership compensation is at the top of Indian pharma bands with material global-principal-aligned LTI architecture. MNC-innovator-India-subsidiary MD compensation routinely ranges ₹8-22 crore fixed with multi-year global-RSU / PSU architectures; Head of Specialty / Head of Rare Disease compensation ranges ₹4-10 crore with launch-and-access-milestone-linked variable; Therapy-Area Head (Oncology / Haematology) compensation ranges ₹3-8 crore; Head of Medical Affairs compensation ranges ₹2.5-6 crore; emerging-biotech Head of R&D compensation frequently includes founder-type equity architectures with ₹2-5 crore cash compensation.
Roles We Typically Place
Why Gladwin International Leadership Advisors for Specialty & Rare Disease
MD / Country Head searches for MNC innovator India subsidiaries.
Head of Specialty / Head of Rare Disease / Head of Innovator-Products placements.
Head of Oncology / Head of Haematology / Head of Immunology / Therapy-Area Head placements.
Head of Medical Affairs / Head of Access / Head of Patient-Programmes placements.
Head of Innovation / Head of R&D placements for emerging biotech operators.
Head of Rare Disease / Head of Orphan Drugs placements.
CFO placements with innovator-and-specialty-accounting credibility.
Organisations We Serve
MNC innovator India subsidiaries (leading global pharma innovator India units across oncology, haematology, immunology, and rare disease; global rare-disease and orphan-drug MNC India units; and global biologics-and-specialty MNC India units)
Listed Indian innovator-and-specialty operators (the specialty-and-proprietary-products arms of the large-cap listed Indian pharma majors and listed Indian innovator-R&D operators)
Listed biosimilars-and-novel-biologics operators and innovator biologics operators
Emerging biotech innovators (India-headquartered oncology-and-discovery biotech operators, cell-and-gene-therapy ventures, India-headquartered mRNA-platform operators, antibiotics-and-anti-infective discovery specialists, and computational-biology specialists)
Rare-disease-focused and orphan-drug specialist operators
Patient-advocacy-aligned and access-programme-focused operators
Specialty & Rare Disease leaders assessed on the Pharma & Biotech “HELIX” framework
Eight dimensions calibrated for pharmaceutical and biotechnology leadership. Dimensions are calibrated for specialty & rare disease mandates where relevant.
Parent Practice
Return to Pharmaceuticals & Biotechnology
Discuss a Specialty & Rare Disease Mandate
Confidential · No obligation
Response within 4 business hours · All enquiries handled by a senior practice partner · Strictly confidential